[DOI] [PMC free article] [PubMed] [Google Scholar] [16].Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torne CW, Ryan DH, Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, N Engl J Med (2023)
Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription
Diabetes 49(4), 611617
Starting at a higher dose or increasing the dose too quickly can increase the risk of adverse events and side effects
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
PA, AMPK inhibitor compound C and GLP-1R antagonist exendin (939) were purchased from Sigma (St